drugset / Trial / NCT02647320
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The hypothesis of this Phase 2, 12-week study, is that DS-8500a will improve glycemic control relative to placebo, based on changes in HbA1c, with acceptable safety and tolerability, in patients with Type 2 Diabetes Mellitus (T2DM) who are treated with metformin.
Timeline
- Start
- 2016-01
- Primary completion
- 2017-01-31
- Completion
- 2017-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FIRUGLIPEL | Small molecule | 25 mg | Oral |
| Subject | FIRUGLIPEL | Small molecule | 50 mg | Oral |
| Subject | FIRUGLIPEL | Small molecule | 75 mg | Oral |
| Comparator | Sitagliptin | Small molecule | 100 mg | Oral |